SOPHiA GENETICS Reports Third Quarter 2026 Results

Impact · against what's priced in

SOPHiA GENETICS shows accelerating operating leverage with EBITDA growth (31%) outpacing revenue growth (25%). The addition of companion diagnostic programs and a multimodal AI project provides concrete catalysts for 2027 revenue streams.

SOPH+0.70

No priced-in read yet

In context

The company reported 25% year-over-year revenue growth and a 31% improvement in adjusted EBITDA, alongside the acquisition of 30 new genomics customers and three BioPharma deals.

Read from the article alone

• earnings
• healthcare
• revenue growth
• ai
• biotech
• SOPH
• biopharma
• ebitda
• genomics
• precision medicine

Search tags